The Neuroscience Estimand Special Interest Group

Scope, objectives and a look into the future

Marisa Bacchi,[1] Marian Mitroiu,[2] Paul Delmar,[3] Rachid Abbas,[3] Hans Ulrich Burger,[3] Andrew Hartley,[4] Mette Krog Josiassen,[5] Lars Lau Raket,[6] Peter Quarg,[7] Khadija Rantell,[8] Nikolaos Sfikas[7]

[1]Consultant, [2]Biogen, [3]F.Hoffmann-La Roche, [3]MHRA, [4]PPD, [5]H.Lundbeck A/S, [6]Lilly, [7]Novartis

Background and Objectives

WG was formed around **2016** aiming to connect statisticians working in Neuroscience

Champion adoption of ICH E9(R1) in Neuroscience drug development

Sharing non-competitive knowledge and experience

Facilitate industry-wide publications

Support and share development and adoption of best practices across industry and regulators

Neuroscience Estimand Ecosystem



Recent Activities

- Parkinson's Disease estimand paper *[Noci, 2022 doi.org/10.1080/19466315.2022.2116476]*
- Migraine estimand manuscript *[in preparation]*
- Multiple Sclerosis estimand manuscript *[in preparation]*
- Alzheimer's Disease estimand posters and PSI webcast *[https://psiweb.org/vod/item/psi-eiwg-webinar-estimands-framework-in-action-the-alzheimer-s-disease-case]*
- Estimands in Neuroscience book chapters *[submitted]*
- Decentralized Trials (DCTs) paper *[Burger, 2023, doi.org/10.1002/bimj.202200370]*

Looking into the future

- Neuroscience Estimand SIG to continue facilitating better understanding of and driving the implementation of the estimands framework using examples and trial methodology in neuroscience
- Extend membership to more stakeholders, including academia and HTA
- As the estimand framework is becoming commonly employed in drug development, the Neuroscience Estimand SIG aims to continue driving the implementation with examples and trial methodology in neuroscience and continues connecting people working in Neuroscience
- We are exploring new topics, including digital endpoints, study designs, and the use of AI.

Interested in joining?

We want to hear from you!

Contact: paul.delmar@roche.com